Michele Petruccelli
Family · Willoughby, OHNPI 1538521000
Payments from drug & device makers
Across 256 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$904
- Lilly USA, LLC$852
- Novo Nordisk$455
- Abbott$322
- AstraZeneca$196
- Amgen$179
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,241100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $904 |
| Lilly USA, LLC | 48 | $852 |
| Novo Nordisk | 35 | $455 |
| Abbott | 17 | $322 |
| AstraZeneca | 13 | $196 |
| Amgen | 10 | $179 |
| Bayer | 9 | $153 |
| Boehringer Ingelheim | 9 | $130 |
| Tandem Diabetes Care, Inc. | 1 | $125 |
| Merck | 7 | $107 |
| Pfizer | 6 | $91 |
| GSK | 4 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Novartis | 4 | $67 |
| Nevro Corp. | 2 | $56 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Johnson & Johnson | 3 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| BETA Bionics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,262 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 404 | $520,606 |
| TrulicityDulaglutide | 217 | $281,599 |
| JardianceEmpagliflozin | 190 | $218,963 |
| MounjaroTirzepatide | 120 | $157,161 |
| FarxigaDapagliflozin Propanediol | 99 | $95,124 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $78,886 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $75,269 |
| Humalog Kwikpen U-100Insulin Lispro | 113 | $64,019 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $59,631 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $47,053 |
| Teriparatide | 16 | $39,850 |
| JanuviaSitagliptin Phosphate | 33 | $33,658 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $31,341 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $22,956 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $21,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $455 | $520,606404 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $852 | $446,268355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $130 | $231,934204 claims |
| AstraZenecaFarxiga | $196 | $95,12499 claims |
| MerckJanuvia | $107 | $33,65833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $74 | $24,14940 claims |
| AbbVieSynthroid, Armour Thyroid | $904 | $5,37387 claims |
| PfizerLevoxyl | $91 | $1,38021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Willoughby
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.